Street Calls of the Week
WISCONSIN/LONDON - Imaging Biometrics (IB), a Wisconsin-based biotechnology company, and UK-based Vivan Therapeutics announced today a strategic research partnership to investigate new cancer applications for gallium maltolate.
The collaboration will utilize Vivan’s proprietary fruit fly screening platform to evaluate gallium maltolate across various tumor profiles, initially focusing on colorectal cancer before expanding to pancreatic, lung, and other gastrointestinal cancers.
Under the agreement, IB will provide gallium maltolate with support from its partner Gallixa, LLC. Vivan will test the compound using its in vivo avatar cancer models, which are designed to mirror various tumor molecular profiles.
The partnership aims to identify therapeutic activity for gallium maltolate as either a standalone treatment or in combination with existing medications. The compound has previously shown promise in glioblastoma treatment, with IB currently evaluating next steps following the closure of its Phase 1 trial for adult glioblastoma.
"This partnership with Vivan Therapeutics marks an exciting new chapter in the exploration of gallium maltolate’s therapeutic potential," said Michael Schmainda, CEO of IB, according to the press release.
Laura Towart, CEO of Vivan Therapeutics, stated that the company’s "ultra-customized in vivo assays have consistently revealed promising therapeutic options," expressing optimism about discovering new applications for gallium maltolate in solid tumors.
The agreement also establishes a framework for potential future joint development efforts, particularly regarding combination therapies, should the screening identify promising opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.